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Introduction: In 2015, the US Alzheimer’s Disease Centers (ADC)
implemented Version 3 of the Uniform Data Set (UDS). This paper
describes the history of Version 3 development and the UDS data
that are freely available to researchers.
Methods: UDS Version 3 was developed after years of coordination
between the National Institute on Aging-appointed Clinical Task
Force (CTF), clinicians from ∼30 ADCs, and the National
Alzheimer’s Coordinating Center (NACC). The CTF recognized
the need for updates to align with the state of the science in
dementia research, while being flexible to the diverse needs and
diseases studied at the ADCs. Version 3 also developed a non-
proprietary neuropsychological battery.
Results: This paper focuses on the substantial Version 3 changes to
the UDS forms related to clinical diagnosis and characterization of
clinical symptoms to match updated consensus-based diagnostic
criteria. Between March 2015 and March 2018, 4820 participants
were enrolled using UDS Version 3. Longitudinal data were
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available for 25,337 of the 37,568 total participants using all UDS
versions.
Discussion: The results from utilization of the UDS highlight the
possibility for numerous research institutions to successfully collabo-
rate, produce, and use standardized data collection instruments for
over a decade.
Key Words: Alzheimer disease center, National Alzheimer’s Coor-
dinating Center, Alzheimer disease, Lewy body disease, fronto-
temporal degeneration, MCI
(Alzheimer Dis Assoc Disord 2018;32:351–358)
I n 1984, the US National Institute on Aging (NIA) of theNational Institutes of Health inaugurated the Alzheimer’s
Disease Centers (ADC) program, aimed at providing a
comprehensive approach to research on Alzheimer disease
(AD) and related disorders. Through their research, ADCs
are expected to aid in early detection, diagnosis, treatment,
and prevention of neurodegenerative disease. As part of the
ADC program, Centers’ data must be collected in a
standardized manner, but also in a way that allows indi-
vidual Centers to maintain their unique research foci and
strategies. To date, the NIA has funded 39 past and present
ADCs that are located at medical institutions across the
United States, and the ADC program has continually
evolved to adapt to the state of the science.
At the start, ADCs collected data primarily retro-
spectively (eg, chart review) as part of the Minimum Data
Set (MDS), with data collection coordinated by the
National Alzheimer’s Coordinating Center (NACC) starting
in 1999. The MDS was a cross-sectional data set consisting
of limited data on demographics, clinical diagnoses, and
neuropathologic findings (when available). It largely served
as a library/cataloging service.
In 2005, ADCs began collecting longitudinal demo-
graphic, clinical, neuropsychological, and diagnostic data
on participants using Version 1 of the Uniform Data Set
(UDS). Details on the data collected and the process of
developing UDS Version 1 can be found elsewhere.1 UDS
Version 2 was implemented in 2008, resulting in a mostly
minor update to the original data collection instruments
such as adding a few new questions to the forms, restruc-
turing of form logic (eg, skip patterns), and adding a few
neuropsychological test elements [eg, Mini Mental State
Exam (MMSE)2 pentagon item score].
In contrast, numerous important changes were made
with the implementation of UDS Version 3, including the
addition of the Form C2 neuropsychological test battery.3
The aims of this paper are to describe the history of devel-
opment and implementation of UDS Version 3, the UDS
data that are currently available, and the types of studies
that can be conducted using this important resource. Pre-
vious published papers focus on the UDS Version 3 neu-
ropsychological test battery only.3,4 This paper describes the
overall development of the UDS Version 3, which consists
of a number of instruments beyond the neuropsychological
test battery; the particular clinical data it collects; and the
supplementary data that are available.
METHODS
The original impetus for the development and adoption
of UDS Version 3 was the desire for an updated neuro-
psychological test battery, details of which have been
thoroughly described elsewhere.3 Some of the benefits of the
updated test battery are that it is nonproprietary and that it
includes a new episodic memory test to reduce practice
effects observed in repeatedly using the prior version.
A primary goal in the development of the UDS Version 3
neuropsychological battery was a set of nonproprietary tests
that would allow sharing and comparison across various
studies. Thus, some of the chosen tests were initially missing
norms with which to reference until sufficient sample size
allowed UDS Version 3 norms to be posted on the NACC
website and to be published in 2018.3 In addition, the new
test battery now captures visuospatial and nonverbal
memory function, domains not previously tested in UDS
Versions 1 and 2. The careful review, evaluation, and
implementation of the new battery took a number of years
and was overseen by the Neuropsychology Work Group, a
subcommittee of the ADCs’ Clinical Task Force (CTF).
Before implementation, the ADCs pilot tested the new
battery (ie, the Crosswalk Study4), which allowed the Neu-
ropsychology Work Group to assess if new and old tests
capturing the same domains could be equated and used in
longitudinal analyses. Results from the crosswalk study
indicated that Version 3 neuropsychological tests were well
correlated with Version 2 tests (ρ= 0.68 to 0.78).4 The
crosswalk study also suggested methods to convert scores on
the Version 3 tests to comparable scores from the Version 2
battery. These conversion factors allow for comparison of
all available initial visit test scores among individuals,
whether they received UDS Version 2 or 3 at baseline, and
for longitudinal comparison of test scores for participants
who received both Version 2 and subsequently Version 3
tests during follow-up.
Along with the neuropsychological test changes, a num-
ber of other substantive edits were made to the forms in Ver-
sion 3. These changes were instituted by the CTF in order to
streamline the forms and adapt to the latest diagnostic criteria,
including biomarker measures. Moreover, new questions were
added to assess clinical characteristics of related neuro-
degenerative disorders [eg, frontotemporal lobar degeneration
(FTLD) mutations, repeated traumatic brain injuries (TBIs)],
reflecting the ADC program’s expanding and diversifying
research priorities. Decisions were made by the entire CTF,
wherein consensus if not unanimity almost always was ach-
ieved whenever possible. The CTF Chair was tasked with
resolving any impasses that arose.
With the goal of streamlining the UDS, the CTF
worked with the NACC to review UDS Version 2, form by
form, identifying questions that were redundant across
forms and opportunities to increase the clarity of the
questions and/or instructions. The decision to eliminate
entire forms or large numbers of items was made by the
CTF if items were both infrequently used by researchers
and deemed no longer necessary to the basic clinical
work-up.
After a comprehensive review of the forms, few data
elements from Version 2 were eliminated due to redundancy,
and a few wording and coding changes were suggested to
clarify data elements. In the end, the major changes
(Table 1) included modifications to the clinical diagnosis
form (Form D1), the removal of the Hachinski Ischemic
Score (Form B2) [given the increased use of magnetic
resonance imaging (MRI) to document ischemic burden]
and the Unified Parkinson’s Disease Rating Scale (UPDRS;
Form B3), and the addition of summary neurological
examination findings (Form B8) and clinician-assessed
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medical conditions (Form D2) forms. Of note, the UPDRS
was incorporated into a module that assesses Lewy body
disorders (LBD module), which ADCs implemented in
August, 2017.
The Clinical Diagnosis Form D1 was updated to not
only adapt to the 2011 National Institute on Aging-
Alzheimer’s Association (NIA-AA) criteria for AD that
incorporated biomarkers [preclinical AD,5 mild cognitive
impairment due to AD (MCI-AD),6 and AD dementia7],
but also to the latest diagnostic criteria for conditions such
as frontotemporal degeneration (eg, behavioral variant
frontotemporal degeneration8 and primary progressive
aphasia9) and vascular brain injury. In addition, Version 3
of Form D1 incorporated new specific questions on AD and
FTLD mutations and on conditions including posterior
cortical atrophy (PCA), multiple system atrophy, human
immunodeficiency virus–associated neurocognitive disorder
(HAND), and psychiatric conditions including bipolar dis-
order and posttraumatic stress disorder. The Neurological
Exam Findings Form B8 was a new addition for Version 3,
aimed at capturing signs from the neurological exam con-
sistent with specific neurodegenerative conditions such as
Parkinson disease (PD), progressive supranuclear palsy,
amyotrophic lateral sclerosis, and cerebrovascular disease.
Finally, Form D2 was added to gather data on medical
conditions that may confer risk for AD or dementia, such as
cardiovascular disease and diabetes, with the goal of
improving reliability and validity compared with the
participant/co-participant self-reported medical conditions
collected on Subject Health History Form A5.
In the months preceding implementation of UDS
Version 3, NACC staff developed the documentation nec-
essary for ADCs to begin using the forms. This included
developing data element dictionaries10 (coding guides for all
variables), guidebooks11 (to guide clinicians on form com-
pletion), neuropsychological battery instructions12 for
clinicians, and data quality checks (to stop or flag poten-
tially erroneous data entry), among other documentation.
The data element dictionaries and accompanying doc-
umentation were provided to ADCs in advance so that they
could program their databases to submit the data to NACC
on the implementation date. In addition, NACC created
electronic forms for ease of data entry and modified the
UDS Oracle database and UDS data submission system to
allow for entry and storage of the Version 3 data. Before
implementation, ADC clinical leaders participated in a
webinar to learn about Version 3 changes and how to
complete the forms. UDS Version 3 was implemented by all
ADCs on March 15, 2015.
In October 2017, the Spanish translation of UDS Ver-
sion 3 became available (Initial and Follow-up Visit Packet;
Neuropsychological Battery). Spanish translation involved
preliminary translation and content review by expert clini-
cians, and pilot testing at 3 US and 4 Latin American sites (see
the Acknowledgments section). Pilot testing revealed minimal
issues with the initial translation for the Montreal Cognitive
TABLE 1. Major Changes Implemented With Version 3 of the Uniform Data Set Initial Visit Packet
Form Major Changes From Version 2 to Version 3
A1: Subject Demographics No major changes to form
A2: Co-participant Demographics No major changes to form
A3: Subject Family History Added questions on: (1) family history of AD and FTLD mutations; (2) diagnosis
and age of onset for family members reported as having cognitive impairment
A4: Subject Medications No major changes to form
A5: Subject Health History* Added questions on: (1) TBI without loss of consciousness and repeated TBI;
(2) sleep disorders (eg, sleep apnea); (3) psychiatric conditions (eg, PTSD,
anxiety); (4) alcohol use/frequency; and (5) medical conditions (eg, diabetes type,
arthritis.) Form is no longer completed at follow-up in lieu of Form D2
B1: Evaluation Form—Physical No major changes to form
B2: Hachinski Ischemic Score Removed altogether (ie, to streamline the UDS)
B3: Unified Parkinson’s Disease Rating Scale Removed altogether (ie, to streamline the UDS)
B4: Clinical Dementia Rating No major changes to form
B5: Neuropsychiatric Inventory Questionnaire No major changes to form
B6: Geriatric Depression Scale No major changes to form
B7: Functional Assessment Scale No major changes to form
B8: Neurological Examination Findings Newly added form assessing neurological findings supportive of clinical diagnoses
(eg, eye movements consistent with PSP)
B9: Clinician Judgment of Symptoms Added questions on: (1) ages of onset of behavioral and motor symptoms;
(2) changes in motor function consisting with ALS
C2: Neuropsychological Battery Scores† Replaced proprietary tests (MMSE, Logical Memory Immediate and Delayed,
BNT, Digit Symbol) with nonproprietary tests: MoCA, Craft Story Immediate
and Delayed, Number Span Forward and Backward, MINT
D1: Clinician Diagnosis Added questions and/or updated diagnostic criteria related to: (1) all-cause
dementia; (2) dementia syndromes (eg, PPA, bvFTD, DLB); (3) etiologic
diagnoses (eg, AD, FTLD, VBI, TBI); (4) biomarker and imaging findings;
(5) presence of AD and FTLD mutations
D2: Clinician-assessed Medical Conditions Newly added form assessing clinician-confirmed medical conditions (eg, diabetes)
*Self-participant and co-participant reported.
†All newly enrolled participants must use Form C2 at their Initial Visit; however, participants originally enrolled using earlier UDS versions can continue
using Form C1 neuropsychological battery during follow-up.
AD indicates Alzheimer disease; ALS, amyotrophic lateral sclerosis; BNT, Boston Naming Test; bvFTD, behavioral variant frontotemporal dementia; DLB,
dementia with Lewy bodies; FTLD, frontotemporal lobar degeneration; MINT, Multilingual Naming Test; MMSE, Mini Mental State Exam; MoCA, Montreal
Cognitive Assessment; PPA, Primary Progressive Aphasia; PSP, progressive supranuclear palsy; PTSD, posttraumatic stress disorder; TBI, traumatic brain
injury; VBI, vascular brain injury.
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Assessment (MoCA) (original Spanish version), Benson
Complex Figure (Copy and Delayed Recall), Number Span
Forward and Backward, Category Fluency (Animals and
Vegetables List Generation), and Trail Making Test Parts A
& B. However, adaption was required for the Craft Story
(Immediate and Delayed Recall), Verbal Fluency: Phonemic
Test (English: words beginning with F and L; Spanish: words
beginning with P and M), and the Multilingual Naming Test
(MINT). Once the Spanish translation became available to
ADCs, the Centers were asked to submit a Linguistic History
form to ascertain levels of acculturation for all UDS partic-
ipants who identify as Hispanic or Latino. In addition to the
Spanish translation, UDS Version 3 has been translated into
Chinese, with plans for use in Alzheimer’s research centers
in China.
RESULTS
Table 1 outlines the major changes to the UDS with
Version 3 implementation. As of March 1, 2018, the UDS
(all versions) contains data on 37,568 participants followed
at 39 past and present ADCs. Longitudinal data (≥ 2 visits)
are available for 25,337 of the participants, with some par-
ticipants having up to 13 UDS visits to date. Version 3
initial visit packets have been submitted on 4820 individuals.
Results reported below are based on data collected from
September 2005 through March 2018 using all 3 UDS
versions.
Approximately 4000 participants were younger than
60 years of age and ∼1000 were 90 years or older at their
initial visit (Table 2). Reflecting the shift in AD research
toward earlier detection, the age demographic shifted to
younger ages when comparing those enrolled using UDS
Version 3 to those enrolled using UDS Version 1 to 2 forms.
In addition, the number of individuals who were asympto-
matic (global Clinical Dementia Rating= 0) increased from
37% among those enrolled using UDS Version 1 to 2 to 46%
among those enrolled using Version 3. Forty-one percent
had at least one apolipoprotein E (APOE) ε4 allele.
Although the large majority of the participants are white
(80%) and non-Hispanic (92%), 4726 participants are
African American, 896 are Asian, and 3079 are Hispanic.
MCI and dementia were clinically diagnosed in 7949 and
13,532 individuals at their initial visit, respectively (Table 3).
ADC clinicians are required to indicate the primary and
contributing etiologic diagnosis for MCI or dementia. AD
was the primary etiologic diagnosis for 40% of those with
MCI and 73% of those with dementia. Among the MCI
participants, primary etiologic diagnoses other than AD were
not as common (eg, 5% LBD, 5% vascular brain injury/
dementia, 4% depression), and in the remainder of dementia
participants, most had a diagnosis of LBD including PD (6%)
or FTLD with behavioral variant frontotemporal degener-
ation or primary progressive aphasia syndromes (12%).
Table 3 additionally provides the number of participants who
have at least 2 UDS visits (ie, longitudinal data) by their
primary etiologic diagnosis at their initial visit. For example,
among MCI participants with a primary etiologic diagnosis of
LBD at their initial visit, 126 completed 2 or 3 UDS visits and
97 completed at least 4 UDS visits.
A number of major additions and edits were made to
Clinician Diagnosis Form D1, including newly collected
information whether the subject had an AD (n= 14) or
FTLD (n= 27) mutation. Table 4 highlights the new
data elements collected with the implementation of UDS












Sample size (n) 32,748 4820 37,568
Age at initial visit [n (%)]
< 60 y 3607 (11.0) 651 (13.5) 4258 (11.3)
60-69 y 8577 (26.2) 1588 (33.0) 10,165 (27.1)
70-79 y 12,028 (36.7) 1897 (39.4) 13,925 (37.1)
80-89 y 7459 (22.8) 638 (13.2) 8097 (21.6)
≥ 90 y 1077 (3.3) 46 (1.0) 1123 (3.0)
Male [n (%)] 14,113 (43.1) 2061 (42.8) 16,174 (43.1)
Education [n (%)]
< 12 y 2924 (9.0) 165 (3.5) 3089 (8.3)
High school
degree
6493 (20.0) 679 (14.3) 7172 (19.3)
Some/completed
college
23,099 (71.0) 3905 (82.2) 27,004 (72.5)
Unknown
Race [n (%)]
White 26,090 (79.7) 3807 (79.0) 29,897 (79.6)
Black/African
American









25 (0.1) 2 (0.0) 27 (0.1)
Asian 757 (2.3) 139 (2.9) 896 (2.4)
Multiracial 1065 (3.3) 106 (2.2) 1171 (3.1)
Unknown 533 (1.6) 85 (1.8) 618 (1.7)
Hispanic ethnicity [n (%)]





834 (2.6) 86 (1.8) 920 (2.5)
Puerto Rican 550 (1.7) 77 (1.6) 627 (1.7)
Cuban 241 (0.7) 95 (2.0) 336 (0.9)
Dominican 256 (0.8) 29 (0.6) 285 (0.8)
Central
American
148 (0.5) 34 (0.7) 182 (0.5)




150 (0.5) 24 (0.5) 174 (0.5)
Ethnicity
unknown
136 (0.4) 19 (0.4) 155 (0.4)
No. UDS visits [n (%)]
1 8902 (27.2) 3329 (69.1) 12,231 (32.6)
2-3 9779 (29.9) 1489 (30.9) 11,268 (30.0)
4-5 6508 (19.9) 2 (0.0) 6510 (17.3)
6-7 3757 (11.5) 0 3757 (10.0)
8+ 3802 (11.6) 0 3802 (10.1)
≥ 1 APOE ε4
allele [n (%)]
10,417 (40.6) 613 (39.4) 11,030 (40.6)
Global CDR at initial visit
[n (%)]
0 12,253 (37.4) 2203 (45.7) 14,456 (38.5)
0.5 11,839 (36.2) 1732 (35.9) 13,571 (36.1)
1 5482 (16.7) 617 (12.8) 6099 (16.2)
2 2046 (6.3) 165 (3.4) 2211 (5.9)
3 1128 (3.4) 103 (2.1) 1231 (3.3)
APOE indicates apolipoprotein E; CDR, Clinical Dementia Rating;
UDS, Uniform Data Set.
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Version 3. Twenty-seven individuals reported having family
members with a known AD mutation (PS1, PS2, or APP),
and 51 reported family with an FTLD mutation (MAPT,
PGRN, C9ORF72, FUS).
With Version 3, additional details are collected on TBI,
including individuals with TBI without loss of consciousness
(n= 320) and repeated TBI (n= 222) (Table 4). Detailed
neurological examination findings on the new Form B8
included parkinsonian signs (n= 471 participants) and
higher cortical visual problem suggesting PCA (n= 143).
A number of diagnoses not previously collected were also
added to Form D1, including PCA syndrome (n= 42 par-
ticipants), FTLD with motor neuron disease (n= 16),
essential tremor (n= 70), symptoms consistent with chronic
traumatic encephalopathy (n= 17), and posttraumatic stress
disorder (n= 32). Finally, the new Clinician-assessed Med-
ical Conditions Form D2 records data on a variety of
clinician-endorsed conditions, including cancer (n= 689
participants), arthritis (n= 2250), and sleep apnea (n= 745).
A substantial number of UDS participants have addi-
tional data sets that are also available at NACC. Neuro-
pathology (NP) data13 are available for 5135 UDS
participants who have died and consented to autopsy
(Table 5). Data from the FTLD module (symptoms, diag-
noses, imaging evidence, and neuropsychological test
findings specific to FTLD) are available for 1324 UDS
participants. MRI are available to download for 4616 par-
ticipants. Among individuals with MRI, 1317 have meas-
ures of regional brain volumes (eg, hippocampal volume).
Amyloid positron emission tomography (PET) is available
for download for 370 participants and cerebrospinal fluid
(CSF) biomarker data for 1100 participants. In addition,
genetic data are available for 13,180 UDS participants by
request from the Alzheimer’s Disease Genetics Consortium
(ADGC), and deoxyribonucleic acid (DNA) samples are
available for 23,381 by request from the National Cell
Repository for Alzheimer’s Disease (NCRAD).
Table 5 provides finer grained details on the number of
participants who have these additional data by their primary
etiologic diagnosis. For instance, the large majority
of individuals (81%) with amyloid PETs available for
TABLE 3. Primary Etiologic Diagnoses for Mild Cognitive Impairment or Dementia at Initial Visit, by Number of Visits



















AD 990 1023 1134 3147 (39.6) 3960 3313 2650 9923 (73.3)
LBD including PD 140 126 97 363 (4.6) 345 316 163 824 (6.1)
FTLD
PSP 10 16 4 30 (0.4) 77 49 12 138 (1.0)
CBD 15 15 5 35 (0.4) 88 70 23 181 (1.3)
MND 1 0 0 1 (0.0) 9 1 0 10 (0.1)
Other (eg, bvFTD) 65 93 67 225 (2.8) 600 597 408 1605 (11.9)
VBI/vascular dementia 151 138 107 396 (5.0) 126 75 54 255 (1.9)
Depression 142 78 87 307 (3.9) 14 2 5 21 (0.2)
Total including other
etiologies
2541 2518 2890 7949 (100.0) 5538 4581 3413 13,532 (100.0)
*Including participants administered any version of the UDS (ie, Version 1, 2, or 3).
AD indicates Alzheimer disease; bvFTD, behavioral variant frontotemporal dementia; CBD, corticobasal degeneration; col, column; FTLD, frontotemporal
lobar degeneration; LBD, Lewy body disease; MCI, mild cognitive impairment; MND, motor neuron disease; PD, Parkinson disease; PSP, progressive
supranuclear palsy.
TABLE 4. Highlights of Data Added to Assessment for Version 3,
By Form




Form A3 (Subject Family History)
Family member(s) with known AD mutation 27 (0.6)
Family member(s) with known FTLD mutation 51 (1.1)
Form A5 (Subject Health History)
TBI without loss of consciousness 320 (6.6)
Repeated TBI 222 (4.6)
Form B8 (Neurological Exam Findings)
Parkinsonian signs 471 (9.8)
Neurological signs consistent with cerebrovascular
disease
143 (3.0)
Higher cortical visual problem suggesting PCA 57 (1.2)
Findings suggestive of PSP, CBS, or related
disorder
134 (2.8)
Findings suggestive of ALS 27 (0.6)
Normal-pressure hydrocephalus: gait apraxia 8 (0.2)
Form D1 (Clinician Diagnosis)
Participant has AD mutation 14 (0.3)
Participant has FTLD mutation 27 (0.6)
PCA syndrome 42 (0.9)
FTLD with motor neuron disease 16 (0.3)
Presumed FTLD subtype
Tauopathy 81 (1.7)
TDP-43 proteinopathy 75 (1.6)
Other/unknown subtype 160 (3.3)
Significant vascular brain injury 305 (6.3)
Essential tremor 70 (1.5)
Symptoms consistent with chronic traumatic
encephalopathy
17 (0.4)
Posttraumatic stress disorder 32 (0.7)
Form D2 (Clinician-assessed Medical Conditions)
Cancer 689 (14.3)
Arthritis 2250 (46.7)
Sleep apnea 745 (15.5)
Antibody-mediated encephalopathy 7 (0.2)
AD indicates Alzheimer’s disease; ALS, amyotrophic lateral sclerosis;
CBS, corticobasal syndrome; FTLD, frontotemporal lobar degeneration;
PCA, Posterior Cortical Atrophy; PSP, primary supranuclear palsy;
TBI, traumatic brain injury.
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download had a clinical diagnosis of normal cognition or
impaired not MCI (some impairment that does not meet
MCI criteria) at their most recent visit, and 166 MCI par-
ticipants and 540 dementia participants with a diagnosis of
LBD (including PD) have DNA samples stored at NCRAD.
DISCUSSION
After considerable deliberation, compromise, and col-
laboration, the CTF, the ADCs, and NACC implemented
UDS Version 3 in March 2015. There was a relatively
lengthy period of evaluation, discussion, and negotiation
amongst the expert ADC clinicians who made up the reg-
ular CTF and those who were part of the associated ad hoc
subcommittees as well as other ADC clinicians. The CTF
considered how to incorporate new developments in the
field, while preserving longitudinal continuity with the
> 10 years of data collected in the prior UDS versions.
Deletions, updates, and additions to the UDS needed to
balance the needs of ∼30 Centers that each have their dis-
tinct research priorities and different participant character-
istics (eg, age, primary diagnosis). Clinician opinion differs
regarding the most important forms and questions to collect
in the UDS within and across multiple ADCs. The CTF
weighed the need to assess key clinical characteristics for the
increasing number of neurodegenerative diseases studied
within the ADC program against the need to keep the UDS
as parsimonious as possible, being mindful of the clinicians’,
research staffs’, and participants’ time. The resulting UDS
Version 3, as in the prior UDS versions, demonstrates the
ability of researchers from numerous institutions to collab-
orate and implement a standardized data collection instru-
ment for over a decade.
An important contribution of the UDS is that it provides
standardized instruments that can be supplemented with
additional modules such as the FTLD and LBD modules,
which were implemented by ADCs in January 2012 and
August 2017, respectively. ADCs voluntarily submit the
modules for individuals suspected to have FTLD or LBD, but
additionally for individuals with AD or controls, which aids in
determining the discriminative capabilities of the module
instruments. To date, 1324 participants have completed the
FTLD module, 464 of which have longitudinal FTLD mod-
ule visits. As of March 2018, the LBD module data have not
accumulated in sufficient numbers to provide to researchers,
but the initial visit forms and documentation for the LBD and
FTLDmodules are viewable on the NACC website (www.alz.
washington.edu/WEB/dataforms_main.html). In addition,
researchers outside of the ADCs may request permission to
use the UDS or associated modules. In the future, additional
modules can be added to the UDS to collect more detailed
data on a specific subpopulation or neurodegenerative disease
(eg, preclinical disease).
The UDS serves as a foundation to integrate not only
standardized clinical assessments of participants with
NACC’s NP data set, but also to incorporate novel MRI,
PET, and CSF biomarker data with these important clinical
characteristics. The NACC database is adaptable and thus
capable of receiving supplemental data such as the imaging
and fluid biomarker data that complement the UDS and
TABLE 5. Additional Data Available on Uniform Data Set Participants by Primary Etiologic Diagnosis at Most Recent Visit















Normal cognition 553 347 1978 689 275 394 6209 8941
Impaired, not MCI 73 33 129 22 25 38 248 981
MCI, etiologic dx
AD 210 37 467 109 24 76 698 2157
LBD including PD 33 10 35 8 1 19 35 179
FTLD
PSP 4 5 0 0 0 0 0 14
CBD 7 12 2 1 0 1 0 19
MND 0 2 0 0 0 0 0 2
Other (eg, bvFTD) 10 58 13 2 0 5 6 81
VBI/vascular dementia 43 4 95 40 3 4 93 287
Total MCI 427 159 806 209 50 160 1083 3780
Dementia, etiologic dx
AD 2721 150 1353 347 17 381 5172 7249
LBD including PD 353 8 114 11 0 34 167 551
FTLD
PSP 86 56 13 1 0 4 7 115
CBD 91 44 10 0 0 7 30 151
MND 5 14 1 0 0 1 1 16
Other (eg, bvFTD) 550 479 98 6 0 29 98 1074
VBI/vascular dementia 93 3 42 16 0 8 116 225
Total dementia 4082 785 1703 397 20 508 5640 9679
Total participants 5135 1324 4616 1317 370 1100 13180 23381
AD indicates Alzheimer disease; ADGC, Alzheimer’s Disease Genetics Consortium; bvFTD, behavioral variant frontotemporal dementia;
CBD, corticobasal degeneration; CSF, cerebrospinal fluid; dx, diagnosis; FTLD, frontotemporal lobar degeneration; LBD, Lewy body disease; MCI, mild
cognitive impairment; MND, motor neuron disease; MRI, magnetic resonance images; NCRAD, National Cell Repository for Alzheimer’s Disease; PD,
Parkinson disease; PET, positron emission tomography; PSP, progressive supranuclear palsy; VBI, vascular brain injury.
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also reflect the trending research priorities of the ADCs.
Along with the data that are either readily available at
NACC or that can be linked to the UDS via the ADGC (eg,
genome-wide association study) or NCRAD (eg, DNA
samples), researchers can supplement the UDS data through
a special request to one or more ADCs to obtain additional
data not available at NACC (requests for UDS data, sup-
plemental data and modules, and special requests for
external data/specimens can be initiated at http://www.alz.
washington.edu). This process of requesting external data
from ADCs is initially coordinated by NACC. As an
example, one such study gained approval from 15 ADCs to
survey participants of 4 different racial/ethnic groups about
their willingness to commit to post mortem brain
donation.14 Researchers also work with NACC to determine
samples of brain tissue that may be available for sharing
from one or more ADCs. An example is a published study
that combined existing NP data at NACC with supple-
mental data on number of microinfarcts through abstraction
of University of Washington and Oregon Health and Sci-
ence University ADC records to examine the associations
between mixed pathologies and domain-specific cognitive
decline.15
The growing depth and breadth of the UDS and of the
additional data that can be linked to the UDS has resulted
in an ever increasing number of published manuscripts using
the NACC data (n= 481 as of March 16, 2018) (viewable
under “Publications and Productivity” link at www.alz.
washington.edu). Early papers using the UDS were limited
in terms of sample size and tended to focus on descriptions
of the UDS sample or various methodological issues. In
contrast, papers published using the UDS data in the first
quarter of 201816–32 investigated a wide range of topics, such
as inappropriate medication use among those with incident
dementia,27 TBI history and early age of onset in autopsy-
confirmed AD,28 big data approaches to preclinical trial
enrichment,24 and predicting sex differences in MCI and AD
using data on white matter hyperintensities and hippo-
campal volume.17 Thus, the demonstrated increase in pub-
lications using UDS data suggests that the UDS revisions
described in this article have tailored the standardized data
collection to measures that are more useful for researchers.
The volume of the published articles and abstracts
using the UDS and the continually increasing diversity of
topics are evidence of the value of the data to junior and
seasoned researchers alike. The strengths of the UDS
include not only the types of data that can be linked to it,
but its longitudinal nature and the availability of sufficient
sample sizes to study rarer conditions or special populations
not otherwise feasible. For instance, UDS data provide
opportunities for finer grain analyses focused on Hispanics/
Latinos of specific origins. In addition, the ability to merge
clinical data with NP data is critical, as NP remains the gold
standard for neurodegenerative diseases such as AD.
Although the UDS exhibits a number of strengths
desirable to researchers, anyone using the data must
acknowledge its weaknesses when conducting a study or
interpreting findings. Recruitment methods for the UDS
sample have varied between ADCs and within each ADC
over time, and are often based on convenience samples such as
recruitment through clinics or participant referrals. The ben-
efit of this approach is that ADCs are able to enrich their
samples with individuals who have or are more likely to
develop neurodegenerative disease. In addition, as mentioned
above, ADCs have distinct research priorities and sample
characteristics. The differences in recruitment and sample
characteristics across the ADCs provide a heterogenous and
diverse group with which to study, but this also means that the
sample is not population-based and thus may not truly reflect
local ADC communities or the larger US population. Another
limitation is that the UDS Version 3 neuropsychological
battery is missing a verbal list learning task such as the Rey
Auditory Verbal Learning Test. The Neuropsychology Work
Group decided against adding a verbal list learning task
because the options were mostly proprietary (a major goal in
developing the UDS 3 battery was to be nonproprietary), and
because of the wide range of verbal list instruments used
across ADCs, which would have created burden on the ADCs
that have long established cohorts using an instrument not
chosen for UDS Version 3. Also, the UDS instruments have
changed over time, which can present a challenge to inves-
tigators wishing to use the longitudinal data (ie, neuro-
psychological test battery changed from UDS Version 2 to 3)
or wishing to use the largest possible samples sizes (definition
of TBI history changed from UDS Version 2 to 3). NACC
developed the researchers data dictionary (RDD-UDS33) to
harmonize data across the UDS versions, whenever possible,
to try to minimize this issue and ensure researchers are aware
of important UDS version changes. In addition, NACC
research staff are available to consult with researchers who
have questions about version changes, or other details about
the UDS data.
UDS Version 3 demonstrates a number of advantages
and improvements over the prior versions, collecting new and
pertinent data in line with the evolving research interests at the
ADCs. UDS Version 3 was developed in a manner that allows
it to be combined with the previous versions, so that the
longitudinal nature of the UDS and the legacy data remain
accessible to researchers. A distinct advantage of UDS Ver-
sion 3 is that it is nonproprietary. With permission, Version 3
can be used in other studies, allowing for a common method
of assessing cognition and clinical characteristics among those
with normal cognition and various neurological diseases and
also providing the ability to compare findings across various
studies and cohorts. Examples of research studies that are
using UDS forms include the Dominantly Inherited Alz-
heimer Network (DIAN), the Advancing Research and
Treatment for Frontotemporal Lobar Degeneration Con-
sortium (ARTFL) and the Longitudinal Evaluation of Fam-
ilial Frontotemporal Dementia Subjects (LEFFTDS). In
addition, the UDS data can be combined with valuable data
internal and external to NACC, including imaging, CSF
biomarker, and genetic data. Since its inception in 2005, the
UDS has highlighted the possibility for numerous research
institutions with sometimes disparate priorities to collaborate
with each other to produce and use standardized data col-
lection instruments. Version 3 was no exception, and with its
implementation, it provides researchers a unique, valuable
resource to facilitate acceleration of novel AD and related
disorders research.
ACKNOWLEDGMENTS
The NACC database is funded by NIA/NIH Grant U01
AG016976. Additional acknowledgements to the Alzheimer’s
Disease Centers are provided in Supplemental Digital
Content 1 (http://links.lww.com/WAD/A207). The authors
thankfully acknowledge all of the faculty and staff at the
ADCs, UDS participants and co-participants, as well as
the following sites for participating in the pilot study of
Alzheimer Dis Assoc Disord  Volume 32, Number 4, October–December 2018 National Alzheimer’s Coordinating Center
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. www.alzheimerjournal.com | 357
the Spanish translation of UDS Version 3: University of
California, San Diego; University of Southern California;
Mount Sinai School of Medicine; Memory Clinic at the
Institute on Aging, Pontificia Universidad Javeriana School of
Medicine, Bogota, Colombia; Fundación para la Lucha
contra las Enfermedades Neurológicas de la Infancia, Buenos
Aires, Argentina; Instituto Nacional de Neurología y Neuro-
cirugía “Manuel Velasco Suárez,” Mexico City, Mexico;
Peru Young-Onset Dementia Network: Universidad Peruana
Cayetano Heredia and Clínica Internacional. Lima, Peru.
REFERENCES
1. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set
(UDS): clinical and cognitive variables and descriptive data
from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord.
2006;20:210–216.
2. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”.
A practical method for grading the cognitive state of patients
for the clinician. J Psychiatr Res. 1975;12:189–198.
3. Weintraub S, Besser L, Dodge HH, et al. Version 3 of the Alzheimer
Disease Centers’ Neuropsychological Test Battery in the Uniform
Data Set (UDS). Alzheimer Dis Assoc Disord. 2018;32:10–17.
4. Monsell SE, Dodge HH, Zhou XH, et al. Results from the
NACC Uniform Data Set Neuropsychological Battery Cross-
walk Study. Alzheimer Dis Assoc Disord. 2016;30:134–139.
5. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the
preclinical stages of Alzheimer’s disease: recommendations
from the National Institute on Aging-Alzheimer’s Association
workgroups on diagnostic guidelines for Alzheimer’s disease.
Alzheimers Dement. 2011;7:280–292.
6. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of
mild cognitive impairment due to Alzheimer’s disease: recom-
mendations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for Alz-
heimer’s disease. Alzheimers Dement. 2011;7:270–279.
7. McKhann GM, Knopman DS, Chertkow H, et al. The
diagnosis of dementia due to Alzheimer’s disease: recommen-
dations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimers Dement. 2011;7:263–269.
8. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of
revised diagnostic criteria for the behavioural variant of
frontotemporal dementia. Brain. 2011;134(pt 9):2456–2477.
9. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classi-
fication of primary progressive aphasia and its variants.
Neurology. 2011;76:1006–1014.
10. National Alzheimer’s Coordinating Center. NACC Uniform
Data Set Data Element Dictionary For Initial Visit Packet.
2015. Available at: www.alz.washington.edu/NONMEMBER/
UDS/DOCS/VER3/ivp_ded.pdf. Accessed April 15, 2018.
11. National Alzheimer’s Coordinating Center. NACCUniformData
Set Coding Guidebook For Initial Visit Packet. 2015. Available at:
www.alz.washington.edu/NONMEMBER/UDS/DOCS/VER3/
UDS3_ivp_guidebook.pdf. Accessed April 14, 2018.
12. National Alzheimer’s Coordinating Center. NACC Uniform
Data Set Instructions for the Neuropsychological Battery (Form
C2). 2015. Available at: www.alz.washington.edu/NONMEMBER/
UDS/DOCS/VER3/UDS3_npsych_instructions_C2.pdf. Accessed
April 14, 2018.
13. Besser LM, Kukull WA, Teylan MA, et al. The revised
National Alzheimer’s Coordinating Center’s Neuropathology
Form—available data and new analyses. J Neuropathol Exp
Neurol. 2018;77:717–726.
14. Boise L, Hinton L, Rosen HJ, et al. Willingness to be a brain
donor: a survey of research volunteers from 4 racial/ethnic
groups. Alzheimer Dis Assoc Disord. 2017;31:135–140.
15. Brenowitz WD, Hubbard RA, Keene CD, et al. Mixed
neuropathologies and associations with domain-specific cogni-
tive decline. Neurology. 2017;89:1773–1781.
16. Agogo GRC, Gnjidic D, Moga D, et al. Longitudinal
associations between different dementia diagnoses and medi-
cation. Int Psychogeriatr. 2018;18:1–11.
17. Burke SL, Hu T, Fava NM, et al. Sex differences in the
development of mild cognitive impairment and probable
Alzheimer’s disease as predicted by hippocampal volume or
white matter hyperintensities. J Women Aging. 2018:1–25.
18. Burke SL, Maramaldi P, Cadet T, et al. Decreasing hazards of
Alzheimer’s disease with the use of antidepressants: mitigating
the risk of depression and apolipoprotein E. Int J Geriatr
Psychiatry. 2018;33:200–211.
19. Cleary EG, Cifuentes M, Grinstein G, et al. Association of low-
level ozone with cognitive decline in older adults. J Alzheimers
Dis. 2018;61:67–78.
20. Davis M, O’Connell T, Johnson S, et al. Estimating
Alzheimer’s disease progression rates from normal cognition
through mild cognitive impairment and stages of dementia.
Curr Alzheimer Res. 2018;15:777–788.
21. de Leon MJ, Pirraglia E, Osorio RS, et al. The nonlinear
relationship between cerebrospinal fluid Abeta42 and tau in
preclinical Alzheimer’s disease. PLoS One. 2018;13:e0191240.
22. Kaur A, Edland SD, Peavy GM. The MoCA-Memory Index
Score: an efficient alternative to paragraph recall for the
detection of amnestic mild cognitive impairment. Alzheimer Dis
Assoc Disord. 2018;32:120–124.
23. Kirson NY, Scott Andrews J, Desai U, et al. Patient
characteristics and outcomes associated with receiving an
earlier versus later diagnosis of probable Alzheimer’s disease.
J Alzheimers Dis. 2018;61:295–307.
24. Lin M, Gong P, Yang T, et al. Big data analytical approaches
to the NACC Dataset: aiding preclinical trial enrichment.
Alzheimer Dis Assoc Disord. 2018;32:18–27.
25. Mitchell JA, Cadet T, Burke S, et al. The paradoxical impact of
companionship on the mental health of older African American
men. J Gerontol B Psychol Sci Soc Sci. 2018;73:230–239.
26. Qian W, Fischer CE, Schweizer TA, et al. Association between
psychosis phenotype and APOE genotype on the clinical
profiles of Alzheimer’s disease. Curr Alzheimer Res. 2018;15:
187–194.
27. Ramsey CM, Gnjidic D, Agogo GO, et al. Longitudinal
patterns of potentially inappropriate medication use following
incident dementia diagnosis. Alzheimers Dement (N Y). 2018;
4:1–10.
28. Schaffert J, LoBue C, White CL, et al. Traumatic brain injury
history is associated with an earlier age of dementia onset in
autopsy-confirmed Alzheimer’s disease. Neuropsychology. 2018;32:
410–416.
29. Stipho F, Jackson R, Sabbagh MN. Pathologically confirmed
Alzheimer’s disease in APOE varepsilon2 homozygotes is rare
but does occur. J Alzheimers Dis. 2018;62:1527–1530.
30. Ting SKS, Foo H, Chia PS, et al. Dyslexic characteristics of
Chinese-speaking semantic variant of primary progressive
aphasia. J Neuropsychiatry Clin Neurosci. 2018;30:31–37.
31. Tse KH, Cheng A, Ma F, et al. DNA damage-associated
oligodendrocyte degeneration precedes amyloid pathology and
contributes to Alzheimer’s disease and dementia. Alzheimers
Dement. 2018;14:664–679.
32. Weintraub S, Besser L, Dodge H, et al. Version 3 of the
Alzheimer’s Disease Centers’ Neuropsychological Test Battery
in the Uniform Data Set. Alzheimer Dis Assoc Disord.
2018;32:10–17.
33. National Alzheimer’s Coordinating Center. NACC Uniform
Data Set Researchers Data Dictionary. 2015. Available at:
www.alz.washington.edu/WEB/rdd_uds.pdf. Accessed April 15,
2018.
Besser et al Alzheimer Dis Assoc Disord  Volume 32, Number 4, October–December 2018
358 | www.alzheimerjournal.com Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
